| Primary information |
|---|
| ID | antitb_1357, |
| Name | 10585872 |
| N-Terminal modification | Gran F2 |
| C-Terminal Modification | VCRTGRSRWRDVCRNFMRRYQSR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Internal disulphide bond at residue between 2-13 |
| Chirality | Cyclic |
| Nature | 23 |
| Source | L |
| Species | Natural |
| Strain | Human cytolytic lymphocytes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv ATCC 25621 |
| Cell Line | IC90 = 30 μM |
| Inhibition Concentration | In vitro |
| Sequence | 1999 |
| Cytotoxicity | Human erythroleukaemia cell line K562 |
| In vivo Model | NA |
| Lethal Dose | 33 % cytolytic activity in range of 3 -7 μM peptide concentration |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against bacillus megaterium, E.coli, P.aeuroginosaand S.aureus |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1875, |
| Name | 28314993 |
| N-Terminal modification | GranF2 |
| C-Terminal Modification | VCRTGRSRWRDVCRNFMRRYQSR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 23 |
| Source | L |
| Origin | Cationic |
| Species | Protein Derived |
| Strain | Peptide derived from Granulysin protein |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv (ATCC 27294) |
| Cell Line | MIC >300 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2017 |
| Cytotoxicity | RBC |
| In vivo Model | NA |
| Lethal Dose | 50% hemolysis at >300 μM |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Streptococcus pneumoniae) |
Tertiary Structure
(Technique) | Not Predicted), |